It is reported that BrainAurora has published the clinical trial results of its core product system in the authoritative peer-reviewed journal A&D, which represents the top academic level of clinical research on cognitive impairment. According to Frost & Sullivan, this paper is the first in the world to confirm the effectiveness of digital therapy for non-dementia vascular cognitive impairment VCIND through evidence-based data from randomized controlled clinical trials.
At the same time, the company was also deeply involved in the release of the first four expert consensuses in the field of digital therapy in China. In 2023, the "Chinese Expert Consensus on Cognitive Digital Therapy 2023" co-authored by the company was officially released. This article systematically defined digital therapy for cognitive impairment for the first time in China, and has won wide recognition from top domestic hospitals and medical professionals.
In addition, the company has actively participated in seven poland telegram data national R&D projects organized by the Ministry of Science and Technology of China, which not only provided it with rich resources and platforms, but also further enhanced its influence and competitiveness in the industry.
China’s first” and global layout, provides a solid foundation for its commercial monetization.
As mentioned earlier, the company's core product, the brain function information management platform software system, is China's first digital therapy product for cognitive impairment that has received regulatory approval. This achievement marks BrainAurora’s pioneering position in the field of digital therapeutics, while also providing patients with a reliable treatment option that has undergone rigorous regulatory certification.